Pharmacokinetic modelling of MRI-based liver function for risk assessment in primary sclerosing cholangitis: a prospective pilot study
Open Access
- 18 June 2026
- journal article
- Published by Springer Nature in European Radiology Experimental
- Vol. 10 (1)
Abstract
Objective: Primary sclerosing cholangitis (PSC) is a rare fibroinflammatory hepatobiliary disease with a highly variable clinical course. Identifying patients at risk for poor outcomes remains challenging. Magnetic resonance imaging (MRI)-based approaches such as DiStrict, Anali score, and relative enhancement (RE) show promise but are limited by operator dependency or static measurements. This study explored pharmacokinetic modelling of liver function as a quantitative imaging biomarker for risk assessment in PSC. Materials and methods: A prospective cohort of 26 PSC patients underwent up to five annual MRI examinations with follow-up up to 7.5 years. Clinical endpoints included liver transplantation, decompensated cirrhosis, and cholangiocarcinoma. Correlation and receiver operating characteristics (ROC) analyses compared the pharmacokinetic model with Anali scores, RE, model for end-stage liver disease (MELD), and the Amsterdam–Oxford Model (AOM). Results: The pharmacokinetic model ( k single ) correlated significantly with MELD ( r = -0.429, p = 0.029), AOM ( r = -0.557, p = 0.003), and endpoint events ( r = -0.605, p = 0.001). ROC analysis showed excellent discrimination for k i,single (area under the curve [AUC] = 0.943) outperformed Anali scores (AUC = 0.800–0.829) and comparable to MELD (AUC = 0.857) and AOM (AUC = 0.900). Conclusion: Pharmacokinetic liver function modelling correlated strongly with MELD and AOM, effectively identifying high-risk PSC patients. Relevance statement: Pharmacokinetic liver function modelling detects functional impairment in PSC, correlating well with established tools such as the AOM. As an objective, quantitative imaging biomarker, this method may complement established risk scores and aid in the identification of patients at risk of adverse outcomes. Key Points: Pharmacokinetic modelling estimates changes in liver function based on MRI. These estimates can be used as a prognostic tool in PSC. The model’s prognostic performance was comparable to established clinical tests.Keywords
Funding Information
- VINNOVA
- Region Östergötland (ALF medel (Avtal om Läkarutbildning och Forskning))
- Vetenskapsrådet (2020-04826)
This publication has 39 references indexed in Scilit:
- Primär sklerosierende Cholangitis – Diagnose und Therapie 2024Die Innere Medizin, 2024
- AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinomaHepatology, 2022
- Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trialEuropean Radiology, 2021
- Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progressionAbdominal Radiology, 2020
- Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring SystemHepatology, 2018
- A New Model for MR Evaluation of Liver Function with Gadoxetic Acid, Including Both Uptake and ExcretionEuropean Radiology, 2018
- Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd‐EOB‐DTPA‐enhanced MRI for hepatic fibrosis stageJournal of Magnetic Resonance Imaging, 2016
- Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progressionHepatology, 2013
- Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot studyEuropean Radiology, 2011
- Assessment of hepatic perfusion parameters with dynamic MRIMagnetic Resonance in Medicine, 2001